RAVER2

Across TCGA pan-cancer cohorts, RAVER2 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of RAVER2’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where RAVER2 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types RAVER2 is over-expressed in tumor, although a few such as HNSC and LUAD show the opposite, repressed pattern.

HNSC, LUAD, and COAD are the cancer types where RAVER2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RAVER2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	All	II,III,IV	−0.333	<.001	11	view →
LUAD	Female	II,III,IV	−0.619	<.001	9	view →
COAD	Female	III,IV	−0.353	<.001	9	view →
LSCC	All	III,IV	−0.322	<.001	7	view →
CCRCC	Male	All	+0.209	<.001	6	view →
PDAC	Male	All	−0.455	<.001	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

RAVER2–HNSC

Open the HNSC breakdown →